COVID19 (disease)

HHS Terminates Funding for GeoVax’s Next-Generation COVID-19 Vaccine: Impacts and Developments

4 days ago talkbio0Tagged BARDA, CHARGE Syndrome, Clinical Trials, COVID19 (disease), development aspects, GeoVax, Immunocompromised Host, pandemic preparedness, Project NextGen, Termination - Inactive Reason Code, Vaccines

GeoVax, HHS, BARDA, Project NextGen, COVID-19 vaccine, GEO-CM04S1, clinical trials, funding termination, immunocompromised, vaccine development, pandemic preparedness

Novavaxs held-up approval package may signal warning for Covid vaccine makers

2 weeks ago talkbio0Tagged Approved, COVID19 (disease), Deferred, Maker (occupation), Market, Novavax 's, United States Food and Drug Administration, Vaccines

Vaccines, Approved, COVID19 (disease), United States Food and Drug Administration, Market, Novavax ‘s, Maker (occupation), Deferred

FDA official said to step in and pause review of Novavax’s COVID-19 vaccine

3 weeks ago talkbio0Tagged Approved, COVID19 (disease), Novavax, Novavax 's, Review [Publication Type], United States Food and Drug Administration, Vaccines

United States Food and Drug Administration, COVID19 (disease), Vaccines, Novavax ‘s, Review [Publication Type], Novavax, Approved

Pfizer Exceeds Q4 Expectations: COVID-19 Products and Cost-Cutting Drive Strong Performance

3 months ago talkbio0Tagged Advice, cost-cutting initiatives, COVID19 (disease), earnings, financial recovery, Pfizer, portfolio, revenue growth

Pfizer, Q4 earnings, COVID-19 portfolio, cost-cutting initiatives, revenue growth, Paxlovid, financial recovery, 2025 guidance

Trump Withdraws US from World Health Organization, Sparking Concerns Over Global Health Security

3 months ago talkbio0Tagged Communicable Diseases, COVID19 (disease), Generalized, health security, Pandemics, public health medicine (field), Transplant Registry Unified Management Program, WHO, Withdraw (activity), World Health Organization

Trump, World Health Organization, WHO, withdrawal, global health security, infectious diseases, pandemics, COVID-19, public health experts.

Moderna Slashes 2025 Revenue Forecast, Expands Cost-Cutting Measures Amid Vaccine Sales Decline

3 months ago talkbio0Tagged 2025, competition, cost-cutting measures, COVID19 (disease), decline, Market, Moderna, Vaccination, Vaccines

Moderna, 2025 revenue forecast, cost-cutting measures, vaccine sales decline, COVID-19 vaccine market competition, falling vaccination rates.

Moderna CEO Reflects on 2024 Challenges and Advances in Shareholder Letter

3 months ago talkbio0Tagged 2024, COVID19 (disease), Letter [Publication Type], Moderna, mRNA medicines, Respiratory syncytial virus, Review [Publication Type], shareholder, Stéphane Bancel, Vaccines

Moderna, shareholder letter, 2024 review, RSV vaccine, COVID-19 vaccine, mRNA medicines, Stéphane Bancel

BioNTech Resolves COVID-19 Vaccine Royalty Disputes with NIH and UPenn

4 months ago talkbio0Tagged Agreement, BioNTech, COVID19 (disease), Disputes, NIH Mouse, Pfizer, Royalty, settlement, UPenn, Vaccines

BioNTech, COVID-19 vaccine, royalty disputes, NIH, UPenn, Pfizer, settlement agreements

Controversial Stanford Professor Jay Bhattacharya Nominated by Trump to Lead NIH Amid Criticism Over Pandemic Views

5 months ago talkbio0Tagged Administration occupational activities, Appointments, Bhattacharya, Controversial, COVID19 (disease), Critic, Jay, NIH Director Nomination, Pandemic Response, Professor, Public Health Research, Stanford University, Transplant Registry Unified Management Program

Jay Bhattacharya, NIH Director Nomination, COVID-19 Pandemic Response Critic, Stanford University Professor, Trump Administration, Public Health Research, Controversial Appointment

Moderna’s COVID-19 Vaccine Sales Exceed Expectations, but RSV Vaccine Falls Short

5 months ago talkbio0Tagged COVID19 (disease), Drug Industry, Moderna, Respiratory syncytial virus, Vaccines

Moderna, COVID-19 vaccine, RSV vaccine, vaccine sales, pharmaceutical industry